[go: up one dir, main page]

EA030330B9 - Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a - Google Patents

Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a

Info

Publication number
EA030330B9
EA030330B9 EA201692264A EA201692264A EA030330B9 EA 030330 B9 EA030330 B9 EA 030330B9 EA 201692264 A EA201692264 A EA 201692264A EA 201692264 A EA201692264 A EA 201692264A EA 030330 B9 EA030330 B9 EA 030330B9
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphodiesterase
inhibitors
triazole derivatives
fused triazole
xrepresents
Prior art date
Application number
EA201692264A
Other languages
English (en)
Other versions
EA030330B1 (ru
EA201692264A1 (ru
Inventor
Рафаль Мощинский-Петковский
Лукаш Боярский
Мацей Вечорек
Якуб Маер
Сильвия Яновская
Миколай Матлока
Малгожата Борковская
Филип Стефаняк
Моника Лямпарска-Пшибыш
Кшиштоф Дубель
Original Assignee
Целон Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Целон Фарма С.А. filed Critical Целон Фарма С.А.
Publication of EA201692264A1 publication Critical patent/EA201692264A1/ru
Publication of EA030330B1 publication Critical patent/EA030330B1/ru
Publication of EA030330B9 publication Critical patent/EA030330B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)

Abstract

В изобретении предложены соединения общей формулы (I), где один из Xи Xпредставляет собой N, другой из Xи Xпредставляет собой -C(CH), A представляет собой незамещенный или замещенный 5-, 6- или 10-членный арил или гетероарил, n равно 0 или 1 и B представляет собой бициклический гетерофрагмент, такой как определено в описании. Предложенные соединения являются ингибиторами фосфодиэстеразы 10A и могут находить применение в медицине для лечения заболеваний или расстройств психических, неврологических или когнитивных функций.
EA201692264A 2014-05-19 2015-05-14 Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a EA030330B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL408251A PL408251A1 (pl) 2014-05-19 2014-05-19 Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
PCT/IB2015/053549 WO2015177688A1 (en) 2014-05-19 2015-05-14 Fused triazole derivatives as phosphodiesterase 10a inhibitors

Publications (3)

Publication Number Publication Date
EA201692264A1 EA201692264A1 (ru) 2017-04-28
EA030330B1 EA030330B1 (ru) 2018-07-31
EA030330B9 true EA030330B9 (ru) 2018-09-28

Family

ID=53434395

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692264A EA030330B9 (ru) 2014-05-19 2015-05-14 Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a

Country Status (17)

Country Link
US (1) US10138245B2 (ru)
EP (1) EP3145930B1 (ru)
JP (1) JP6455947B2 (ru)
KR (1) KR102404650B1 (ru)
CN (1) CN106459060B (ru)
AU (1) AU2015263013B2 (ru)
CA (1) CA2946258C (ru)
DK (1) DK3145930T3 (ru)
EA (1) EA030330B9 (ru)
ES (1) ES2688084T3 (ru)
HR (1) HRP20181027T1 (ru)
HU (1) HUE039847T2 (ru)
MX (1) MX367647B (ru)
PL (2) PL408251A1 (ru)
PT (1) PT3145930T (ru)
SI (1) SI3145930T1 (ru)
WO (1) WO2015177688A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017007301A1 (en) * 2015-07-06 2017-01-12 Universiti Sains Malaysia Compound and method for inhibiting sirtuin activities
KR102587382B1 (ko) * 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
CN111410657B (zh) * 2019-01-08 2024-05-21 北京鼎材科技有限公司 一种发光材料及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053168A1 (en) * 2007-07-17 2009-02-26 Richard Rickles Treatments of b-cell proliferative disorders
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8975276B2 (en) * 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10

Also Published As

Publication number Publication date
WO2015177688A1 (en) 2015-11-26
HRP20181027T1 (hr) 2018-08-24
SI3145930T1 (sl) 2018-10-30
EA030330B1 (ru) 2018-07-31
US10138245B2 (en) 2018-11-27
CN106459060A (zh) 2017-02-22
HUE039847T2 (hu) 2019-02-28
MX367647B (es) 2019-08-29
CN106459060B (zh) 2019-04-05
CA2946258C (en) 2023-06-06
AU2015263013A1 (en) 2016-11-17
PT3145930T (pt) 2018-10-11
ES2688084T3 (es) 2018-10-30
AU2015263013B2 (en) 2018-10-04
MX2016015180A (es) 2017-03-23
KR20170005860A (ko) 2017-01-16
DK3145930T3 (en) 2018-09-24
EP3145930B1 (en) 2018-07-04
PL408251A1 (pl) 2015-11-23
KR102404650B1 (ko) 2022-06-02
EP3145930A1 (en) 2017-03-29
JP2017521364A (ja) 2017-08-03
EA201692264A1 (ru) 2017-04-28
CA2946258A1 (en) 2015-11-26
PL3145930T3 (pl) 2018-11-30
JP6455947B2 (ja) 2019-01-23
US20170114064A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA202092442A3 (ru) Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
JOP20180116A1 (ar) H1- بيرازولو [4، 3-b] بيريدينات كمثبطات PDE1
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA030330B9 (ru) Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
GEP20196961B (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
SA521422152B1 (ar) Vanin مركبات عطرية غير متجانسة كمثبطات
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
MX2019014876A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EA202090414A1 (ru) Соединения и их применение
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
EA201990399A1 (ru) Соединения, композиции и их применение
EA201692227A1 (ru) Производные сложных аминоэфиров
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX373817B (es) Inhibidores de 3,5-diaminopirazol quinasa.
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
EP3515915A4 (en) Process for preparing beta-lactamase inhibitor hydroxylurea intermediates
MX375329B (es) 2,2,2-trifluoroetil-tiadiazinas.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM